Requirement for transcription factor NFAT in interleukin-2 expression
dc.contributor.author | Chow, Chi-Wing | |
dc.contributor.author | Rincon, Mercedes | |
dc.contributor.author | Davis, Roger J. | |
dc.date | 2022-08-11T08:09:33.000 | |
dc.date.accessioned | 2022-08-23T16:35:31Z | |
dc.date.available | 2022-08-23T16:35:31Z | |
dc.date.issued | 1999-02-18 | |
dc.date.submitted | 2009-03-24 | |
dc.identifier.citation | Mol Cell Biol. 1999 Mar;19(3):2300-7. | |
dc.identifier.issn | 0270-7306 (Print) | |
dc.identifier.pmid | 10022916 | |
dc.identifier.uri | http://hdl.handle.net/20.500.14038/38578 | |
dc.description.abstract | The nuclear factor of activated T cells (NFAT) transcription factor is implicated in expression of the cytokine interleukin-2 (IL-2). Binding sites for NFAT are located in the IL-2 promoter. Furthermore, pharmacological studies demonstrate that the drug cyclosporin A inhibits both NFAT activation and IL-2 expression. However, targeted disruption of the NFAT1 and NFAT2 genes in mice does not cause decreased IL-2 secretion. The role of NFAT in IL-2 gene expression is therefore unclear. Here we report the construction of a dominant-negative NFAT mutant (dnNFAT) that selectively inhibits NFAT-mediated gene expression. The inhibitory effect of dnNFAT is mediated by suppression of activation-induced nuclear translocation of NFAT. Expression of dnNFAT in cultured T cells caused inhibition of IL-2 promoter activity and decreased expression of IL-2 protein. Similarly, expression of dnNFAT in transgenic mice also caused decreased IL-2 gene expression. These data demonstrate that NFAT is a critical component of the signaling pathway that regulates IL-2 expression. | |
dc.language.iso | en_US | |
dc.relation | <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=10022916&dopt=Abstract">Link to Article in PubMed</a> | |
dc.subject | Animals | |
dc.subject | COS Cells | |
dc.subject | Cell Line | |
dc.subject | Cricetinae | |
dc.subject | DNA-Binding Proteins | |
dc.subject | *Gene Expression Regulation | |
dc.subject | Humans | |
dc.subject | Interleukin-2 | |
dc.subject | Jurkat Cells | |
dc.subject | Mice | |
dc.subject | Mice, Transgenic | |
dc.subject | NFATC Transcription Factors | |
dc.subject | *Nuclear Proteins | |
dc.subject | Transcription Factors | |
dc.subject | Transcription, Genetic | |
dc.subject | Life Sciences | |
dc.subject | Medicine and Health Sciences | |
dc.title | Requirement for transcription factor NFAT in interleukin-2 expression | |
dc.type | Journal Article | |
dc.source.journaltitle | Molecular and cellular biology | |
dc.source.volume | 19 | |
dc.source.issue | 3 | |
dc.identifier.legacyfulltext | https://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=2443&context=oapubs&unstamped=1 | |
dc.identifier.legacycoverpage | https://escholarship.umassmed.edu/oapubs/1444 | |
dc.identifier.contextkey | 794941 | |
refterms.dateFOA | 2022-08-23T16:35:31Z | |
html.description.abstract | <p>The nuclear factor of activated T cells (NFAT) transcription factor is implicated in expression of the cytokine interleukin-2 (IL-2). Binding sites for NFAT are located in the IL-2 promoter. Furthermore, pharmacological studies demonstrate that the drug cyclosporin A inhibits both NFAT activation and IL-2 expression. However, targeted disruption of the NFAT1 and NFAT2 genes in mice does not cause decreased IL-2 secretion. The role of NFAT in IL-2 gene expression is therefore unclear. Here we report the construction of a dominant-negative NFAT mutant (dnNFAT) that selectively inhibits NFAT-mediated gene expression. The inhibitory effect of dnNFAT is mediated by suppression of activation-induced nuclear translocation of NFAT. Expression of dnNFAT in cultured T cells caused inhibition of IL-2 promoter activity and decreased expression of IL-2 protein. Similarly, expression of dnNFAT in transgenic mice also caused decreased IL-2 gene expression. These data demonstrate that NFAT is a critical component of the signaling pathway that regulates IL-2 expression.</p> | |
dc.identifier.submissionpath | oapubs/1444 | |
dc.contributor.department | Howard Hughes Medical Institute and Program in Molecular Medicine | |
dc.source.pages | 2300-7 |